StreetInsider.com News Articles

Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 8c

Tue, 04 Aug 2026 07:24:56 -0400

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

Form 10-Q Larimar Therapeutics, For: Jun 30

Tue, 04 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260804/26861487.html

Form 10-Q Larimar Therapeutics, For: Jun 30

Tue, 04 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260804/26861487.html

Form 8-K Larimar Therapeutics, For: Aug 04

Tue, 04 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26861396.html

Form 8-K Larimar Therapeutics, For: Aug 04

Tue, 04 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26861396.html

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Form 4 Larimar Therapeutics, For: Jul 06 Filed by: Hamilton Thomas Edward

Wed, 08 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260708/26747571.html

Form 4 Larimar Therapeutics, For: Jul 06 Filed by: Hamilton Thomas Edward

Wed, 08 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260708/26747571.html

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).
The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’

H.C. Wainwright Assumes Larimar Therapeutics (LRMR) at Buy

Thu, 02 Jul 2026 06:46:59 -0400
(Updated - July 2, 2026 6:46 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju assumes coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Buy rating and a price target of $10.00.
The analyst comments "BLA submission completion seeking accelerated approval on track for 2H26—assuming coverage at Buy. We are assuming coverage of Larimar Therapeutics with a Buy rating and 12-month price target of $10 per share. Investors are reminded that Larimar is gearing up to complete its Biologics License Application (BLA) for nomlabofusp later this year; in our view, the filing is likely to receive Priority Review. Nomlabofusp is a subcutaneously administered, recombinant

H.C. Wainwright Assumes Larimar Therapeutics (LRMR) at Buy

Thu, 02 Jul 2026 06:46:59 -0400
(Updated - July 2, 2026 6:46 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju assumes coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Buy rating and a price target of $10.00.
The analyst comments "BLA submission completion seeking accelerated approval on track for 2H26—assuming coverage at Buy. We are assuming coverage of Larimar Therapeutics with a Buy rating and 12-month price target of $10 per share. Investors are reminded that Larimar is gearing up to complete its Biologics License Application (BLA) for nomlabofusp later this year; in our view, the filing is likely to receive Priority Review. Nomlabofusp is a subcutaneously administered, recombinant

Larimar Therapeutics (LRMR) PT Lowered to $5 at Baird

Tue, 30 Jun 2026 06:54:02 -0400
Baird analyst Joel Beatty lowered the price target on Larimar Therapeutics (NASDAQ: LRMR) to $5.00 (from $7.00) while maintaining a Outperform rating.

Form 8-K Larimar Therapeutics, For: Jun 29

Mon, 29 Jun 2026 06:34:00 -0400
si-local-file:///var/storage/secattach/20260629/26701658.html

Form 8-K Larimar Therapeutics, For: Jun 29

Mon, 29 Jun 2026 06:34:00 -0400
si-local-file:///var/storage/secattach/20260629/26701658.html

Larimar files first BLA module for Friedreich's ataxia drug

Mon, 29 Jun 2026 06:30:57 -0400

Larimar Therapeutics (Nasdaq: LRMR) submitted the first module of a rolling Biologics License Application (BLA) to the Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for Friedreich's ataxia (FA), a rare progressive neurological disease. The remaining modules are expected in the second half of 2026.
The submission follows FDA meeting minutes from a Type B multidisciplinary pre-BLA meeting, in which the agency confirmed the existing data package appears sufficient to support a BLA submission seeking accelerated approval, with skin frataxin (FXN) as a potential novel surrogate endpoint. The FDA also agreed to a rolling submission format.
Larimar also released updated